FDA Tested 75 Tattoo Inks. A Third Were Contaminated — and "Sterile" on the Label Meant Nothing.

FDA scientists bought 75 tattoo and permanent-make-up inks off the American market and cultured them. 26 came back contaminated — 34.7 percent.

The finding that should change how you buy: they found no significant association between a "sterile" claim on the label and the actual absence of bacteria. Inks marked sterile were not reliably sterile. The word is doing no work.

What was in them

Across the contaminated bottles the team recovered 34 bacterial isolates spanning 14 genera and 22 species, and judged 19 of the 34 to be possibly pathogenic. Anaerobic organisms turned up too — relevant because a tattoo needle deposits ink into exactly the low-oxygen environment those thrive in.

A separate chemistry study of 54 inks from nine US manufacturers found something just as awkward. 45 of the 54 — 83 percent — contained pigments or additives that were not on the label. Only six matched their labels exactly. Propylene glycol, a recognised allergen, was present in 15 inks and declared on none of them.

If a client has a reaction and you go to the label to work out why, the label may not know either.

Dilution is where it gets worse

Italian researchers tested what happens when black ink is thinned for greywash. Undiluted sterile black ink killed nearly everything put into it. At 100-fold dilution, most species survived ten weeks — and Pseudomonas aeruginosa, Mycobacterium fortuitum and Candida albicans actively grew.

That is not theoretical. In 2023 the CDC and Oregon Health Authority traced eight Mycobacterium immunogenum infections to a single Oregon studio. The likely vehicle was not the ink as sold — it was the artist's own self-prepared diluent.

The practical read: your sterile ink stops being sterile the moment you thin it with something that isn't.

The legal oddity nobody mentions

Here is the part most American artists have never been told.

Pigments in tattoo ink are colour additives, and colour additives require premarket approval. No colour additive has ever been approved for injection into skin. FDA's own fact sheet says it "traditionally has not exercised regulatory authority" over this.

Read literally, essentially every tattoo ink sold in the United States is technically adulterated. FDA has simply chosen not to act on that for decades. California is the one state that requires you to tell clients as much — Health & Safety Code § 119303(a)(4) obliges artists to disclose that the inks "have not been approved by the federal Food and Drug Administration."

What MoCRA changed — and the exemption that does not apply to you

The Modernization of Cosmetics Regulation Act, enacted 29 December 2022, gave FDA mandatory recall authority over cosmetics for the first time, including tattoo inks. It can now force a recall where a product is adulterated or misbranded and will cause serious health consequences, and the responsible person refuses to recall voluntarily. It can suspend a facility's registration, after which shipping from that facility is a prohibited act.

It also brought registration and listing duties, with a compliance date of 1 July 2024. Facility registration renews every two years; product listings update annually. Serious adverse events must be reported to FDA within 15 business days — and "infection" and "significant disfigurement… serious and persistent rashes" are named in the statute as serious adverse events.

The point manufacturers keep missing: MoCRA's small-business exemptions from good manufacturing practice, facility registration and product listing expressly do not apply to products that are injected, nor to products that alter appearance for more than 24 hours where the consumer cannot remove them. Tattoo ink meets both tests. There is no small-manufacturer relief for ink.

What has not happened: cosmetic GMP regulations are still only draft guidance. The October 2024 FDA guidance on insanitary conditions in ink manufacturing is headed "Contains Nonbinding Recommendations" — it recommends microbial testing and sterilisation, it does not require them.

Only two federal actions in three years

Despite all of the above, FDA has taken exactly two publicly posted actions on tattoo ink between 2023 and July 2026.

• 7 May 2025 — a safety advisory (not a recall) against two Sacred Tattoo Ink products, Raven Black lot RB0624 and Sunny Daze lot SD1124, for pathogenic organisms including Pseudomonas aeruginosa, found through routine marketplace surveillance.
• 23 August 2024 — a voluntary recall by Sierra Stain LLC of three Bloodline water-based pigments after FDA's own sampling found high concentrations of microorganisms. Distributed to all fifty states through Amazon. No illnesses reported. The firm is now out of business.

Three things the trade press keeps getting wrong

We checked the claims circulating in tattoo coverage against FDA's databases directly, because these name brands and getting them wrong is unfair to the companies involved.

• The Fusion Ink recall is from autumn 2017. It is still being written up as though it were current. There is no 2023–2026 Fusion recall.
• The advisory naming Scalpaink, Dynamic Color and Solid Ink is dated 15 May 2019. The page's underlying metadata shows a 2024 date, but that is a content-system migration artefact, not a new action.
• No FDA warning letter concerns tattoo ink. All eighteen "tattoo" hits in the warning-letter database are numbing creams sold as unapproved drugs. A search for "tattoo pigment" returns nothing.

And the cancer question, stated properly

A 2024 Swedish study reporting a lymphoma association got heavy coverage. Its incidence rate ratio was 1.21 with a confidence interval of 0.99 to 1.48 — the interval crosses 1.0, so it is not statistically significant. The authors found no dose–response with tattooed body area, which materially weakens any causal reading, and the strongest signal appeared within two years of a first tattoo, a window too short for a latency-requiring mechanism.

A 2025 meta-analysis pooling 17,941 participants across four studies found an odds ratio of 1.01 for non-Hodgkin lymphoma. The authors stated that none of the included studies demonstrated a statistically proven link, and rated the certainty of evidence LOW.

There is an association worth studying. There is not, on this evidence, a demonstrated cause. Anyone telling your clients otherwise is ahead of the data.

What to actually do

• Treat "sterile" on a label as marketing, not a test result. FDA's own data says it does not predict sterility.
• Do not make your own diluent. The Oregon outbreak came through one, and diluted ink supports growth that neat ink kills.
• Assume the label is incomplete. With 83% carrying undeclared ingredients, a client's allergy history is worth more than an ingredient list.
• If you manufacture or rebottle, you are registered. There is no small-business exemption for injected products, and renewals are falling due now.
• Report serious reactions. Infection and persistent rashes are named in the statute, the clock is 15 business days, and FDA's surveillance is only as good as what reaches it.

Where this is uncertain

FDA's recall database returns exactly one tattoo record. However, Class II and III recalls that appear only in the weekly Enforcement Report without a press release would not show up there, and that system needs credentials we do not have. A modest possibility of unlisted classified recalls remains, so treat "two actions" as two publicly posted actions rather than a guarantee of completeness.

One research note worth passing on: every fda.gov page returns a 404 to automated fetchers. That is bot detection, not a missing page. Anyone repeating this work should not conclude an FDA page is gone because a script could not open it — the pages cited here are all live.